Skip to main navigation Skip to search Skip to main content

SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer

  • Guy A. Van Hazel
  • , Volker Heinemann
  • , Navesh K. Sharma
  • , Michael P.N. Findlay
  • , Jens Ricke
  • , Marc Peeters
  • , David Perez
  • , Bridget A. Robinson
  • , Andrew H. Strickland
  • , Tom Ferguson
  • , Javier Rodríguez
  • , Hendrik Kröning
  • , Ido Wolf
  • , Vinod Ganju
  • , Euan Walpole
  • , Eveline Boucher
  • , Thomas Tichler
  • , Einat Shacham-Shmueli
  • , Alex Powell
  • , Paul Eliadis
    • Richard Isaacs, David Price, Fred Moeslein, Julien Taieb, Geoff Bower, Val Gebski, Mark Van Buskirk, David N. Cade, Kenneth Thurston, Peter Gibbs

Research output: Contribution to journal › Article › peer-review

303   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science